17.7 C
New York
Wednesday, June 17, 2026

Tag: rna

newssourceFORcompanyinformationcontent1marketreleases

Zymo Research Offers Reliable Domestic Solutions Amid Offshore Supply Chain Challenges

IRVINE, Calif., June 18, 2025 /PRNewswire/ -- As research and diagnostic companies grapple with rising prices and persistent backorders from offshore suppliers, Zymo Research is...

Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®

The Oligonucleotide Synthesis Market is poised for robust growth, fueled by advancements in personalized medicine, molecular diagnostics, and genomics research. However, high production costs, regulatory...

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round.

Chronic Hepatitis B Market–The US to Have the Lion’s Share Among the 7MM, Predicts DelveInsight

The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and rising awareness about early...

New England Biolabs® Announces Winners of the 2025 Monarch Nucleic Acid Purification Scholarship

Three recipients were recognized for research exemplifying the core tenets of Monarch – performance, sustainability and value. IPSWICH, Mass., June 12, 2025 /PRNewswire/ -- New...

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...

Insmed Announces Proposed $650 Million Public Offering of Common Stock

BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...

“STRONGER TOGETHER”: SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION”, ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON...

Swiss biotech excellence returns to BIO 2025 in Boston, where Switzerland Global Enterprise presents 45 cutting-edge Swiss companies at the SWISS BIOTECH pavilion, booth...

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD...

-- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D., Professor of...

Messenger RNA Market Research Report 2025-2035, Competitive Analysis of Pfizer, GSK, Arcturus Therapeutics, AstraZeneca, Beam Therapeutics, Moderna, Oncotelic, SK Bioscience, Sangamo, Sanofi CureVac

mRNA Market Surges: The global mRNA market is booming, fueled by the success of COVID-19 vaccines, with applications expanding to cancer and genetic disorders. Driven by public-private investments, the industry sees pharmaceutical giants like Pfizer and Moderna spearheading innovations. Despite challenges such as high costs, the market is set for substantial growth through 2035, with North America leading due to its robust healthcare infrastructure. Recent collaborations, such as Etherna Immunotherapies with Dropshot Therapeutics, are further accelerating RNA therapeutic developments. 
mRNA Market Surges: The global mRNA market is booming, fueled by the success of COVID-19 vaccines, with applications expanding to cancer and genetic disorders. Driven by public-private investments, the industry sees pharmaceutical giants like Pfizer and Moderna spearheading innovations. Despite challenges such as high costs, the market is set for substantial growth through 2035, with North America leading due to its robust healthcare infrastructure. Recent collaborations, such as Etherna Immunotherapies with Dropshot Therapeutics, are further accelerating RNA therapeutic developments.

Kanazawa University research: High-speed AFM and 3D modelling help towards understanding the dynamics of a protein implicated in several cancers

KANAZAWA, Japan, June 11, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University observe and model how the enzyme ADAR1 interacts...

Exosome Research Market worth US$480.6 million by 2030 with 17.5% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., June 10, 2025 /PRNewswire/ -- The global Exosome Research Market, valued at US$189.4 million in 2024 stood at US$214.4 million in 2025...

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event “Is the Beaten Down Biotech Sector the Smartest Bet in Today’s...

Featuring Serina Therapeutics’ CEO - Wednesday, June 11, 2025

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRna

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers